打开APP

他汀类药物或可降低个体癌症死亡的风险

  1. 他汀类药物
  2. 死亡
  3. 癌症
  4. 降胆固醇
  5. 风险

来源:生物谷 2015-06-08 15:43

近日,在芝加哥召开的美国临床肿瘤学会会议上,来自斯坦福大学的研究人员表示,女性服用降低胆固醇水平的他汀类药物似乎会降低其因癌症死亡的风险。

2015年6月8日 讯 /生物谷BIOON/ --近日,在芝加哥召开的美国临床肿瘤学会会议上,来自斯坦福大学的研究人员表示,女性服用降低胆固醇水平的他汀类药物似乎会降低其因癌症死亡的风险。

但英国的研究者表示,需要进行随机的试验来证实是否该研究直接取决于他汀类药物的效应;研究者对年龄在50至79岁间的15万名绝经后女性进行了长达15年的跟踪研究,在研究期间有3100名女性因癌症死亡;那些服用降胆固醇药物的个体相比未服用药物的个体而言因癌症死亡的可能性降低了。

研究者表示,服用他汀类药物或可降低个体因常见癌症死亡的风险,包括乳腺癌、结直肠癌和卵巢癌等;但个体患肺癌的死亡率却并没有任何变化,当考虑到所有癌症时,在整个研究过程中,研究者发现服用他汀类药物因癌症死亡的可能性会少20%;本文研究同时也考虑了影响癌症风险的因素,比如家族史、年龄、BMI指数以及吸烟风险等。

研究者Richard Roope表示,本文研究并没有证明绝经后女性应当服用他汀类药物来降低因癌症死亡的风险;我们并不确定是否癌症死亡风险的降低和他汀类药物的使用直接相关,有可能是取决于别的因素。本文研究并没有证明他汀类药物是个体因癌症死亡率降低的原因,后期还需要更多研究来证明。

此前研究表明胆固醇或许可以帮助癌症扩散,而本文研究中研究者在不同研究组女性患者的比率上并没有发现任何差异,而仅仅是在个体因疾病死亡的风险上发现了差异;后期研究者们将去研究是否他汀类药物可以帮助治疗某些癌症,研究者希望进行更多深入的研究来确定是否更多女性可以得益于他汀类药物。(生物谷Bioon.com)

本文系生物谷原创编译整理,欢迎转载!转载请注明来源并附原文链接。更多资讯请下载生物谷APP.

PMC:

PMID:

Statin use and all-cancer mortality: Prospective results from the Women’s Health Initiative.

Ange Wang, Aaron K Aragaki, Jean Y. Tang, Allison W. Kurian, JoAnn E Manson, Rowan T. Chlebowski, Michael S. Simon, Pinkal M. Desai, Sylvia Wassertheil-Smoller, Simin Liu, Stephen Kritchevsky, Heather A. Wakelee, Marcia L. Stefanick; Stanford Univ School of Medcn, South Pasadena, CA; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA; Stanford University School of Medicine, Redwood City, CA; Stanford University Medical Center, Stanford, CA; Brigham and Women's Hospital/Harvard Medical School, Boston, MA; Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA; Karmanos Cancer Inst, Detroit, MI; Weill Cornell Medcll Coll, Starr 3, NY; Albert Einstein College of Medicine, Bronx, NY; Brown University, Providence, RI; Wake Forest University, School of Medicine, Winston-Salem, NC; Stanford Cancer Institute/Stanford University School of Medicine, Stanford, CA; Stanford Prevention Research Center, Stanford, CA

Background: Statin medications are widely used for lipid lowering and heart disease prevention. Retrospective studies and basic scientific evidence have suggested that statins may also reduce cancer mortality. Data fromthe Women’s Health Initiative Observational Study (WHI-OS) and Clinical Trial (WHI-CT) were used to investigate the association between statin use and all-cancer mortality in a prospective cohort of postmenopausal women. Methods: The WHI study enrolled women aged 50-79 from 1993-1998 at 40 U.S. clinical centers. Among 146,326 participants with median 14.6 follow-up years, 23,067 incident cancers and 3,152 cancer deaths were observed. Cox proportional hazards models were used to investigate the relationship between statin use (as a time-dependent exposure) and cancer mortality. Analyses were adjusted for age, race/ethnicity, education, smoking, body mass index, physical activity, family history of cancer, current health care provider, hormone use, age at menarche, solar irradiance, and history of heart disease/diabetes. Results: Compared with never users, current statin use was associated with significantly decreased cancer mortality (HR 0.78; 95% CI 0.71-0.86). Use of other lipid lowering medications was associated with a similar reduction in cancer deaths compared to monotherapy statin use (p-het = 0.57). The reduction in cancer death associated with statin use was not dependent on statin potency (p-het = 0.22), lipophilicity/hydrophilicity (p-het = 0.43), type (p-het = 0.34) or duration (p-het = 0.33). Current statin use was associated with significantly decreased mortality of multiple cancer types, including breast, colorectal, ovarian, digestive, and bone/connective tissue cancer deaths, but not lung cancer. However, past statin users were not at lower risk of cancer death compared to never users (HR 1.06; 95% CI, 0.85-1.33); additionally, statin use was not associated with a reduction in cancer incidence despite its effect on mortality (HR, 0.96; 95% CI: 0.92-1.001). Conclusions: In a cohort of postmenopausal women, regular use of statins or other lipid-lowering medications may decrease cancer mortality, regardless of the type, duration, or potency of statin medications used. Clinical trial information: NCT00000611

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->